Skip to content

To Explore the Feasibility of Minimal Residual Disease (MRD) as a Prognostic Marker in Patients with T2 Renal Cell Carcinoma

To Explore the Feasibility of Minimal Residual Disease (MRD) as a Prognostic Marker in Patients with T2 Renal Cell Carcinoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061783
Enrollment
Unknown
Registered
2022-07-02
Start date
2022-06-20
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2 Renal Cell Carcinoma

Interventions

control group:none

Sponsors

The Changhai Hospital of Naval Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with renal cell carcinoma and meeting the following criteria: 1. Male or female aged >= 18 years old and <= 80 years old who are willing to sign the informed consent form; 2. PET-CT before operation confirmed that there is no metastatic disease; 3. Patients with pT2N0M0 clear cell renal cell carcinoma diagnosed by imaging and pathology examination. The first-line treatment is partial nephrectomy or radical nephrectomy. There were no tumor cells at the surgical margin; 4. No history of other kinds of cancer.

Exclusion criteria

Exclusion criteria: 1. Patients with anatomic or functional isolated kidney; 2. Pregnant or lactating women, or patients who are fertile but do not take contraceptive measures; 3. Severe infection; 4. Severe heart disease; 5. Uncontrollable neurological or mental disorders; 6. Severe diabetes mellitus; 7. Patients with severe autoimmune diseases.

Design outcomes

Primary

MeasureTime frame
minimal residual disease;Whole exon sequencing of surgical specimens;

Countries

China

Contacts

Public ContactLinhui Wang

The Changhai Hospital of Naval Medical University

wanglinhuicz@163.com+86 13901635510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026